 |
32 Diseases |  |
11 Trials |
|
11 Trials |  |
1696 News |  |
| «12...9101112131415161718192021» |
- Adempas (riociguat) / Bayer, Merck (MSD)
Enrollment open, Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Mar 22, 2016
P1, N=40, Recruiting, Sponsor: Bayer
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2018 --> Dec 2016
- Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
Enrollment open: HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - Mar 8, 2016
P1, N=20, Enrolling by invitation, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting --> Recruiting | Trial primary completion date: Jan 2018 --> Dec 2016 Not yet recruiting --> Enrolling by invitation
- ||||||| Prezista (darunavir) / J&J
Trial completion, Combination therapy: TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options (clinicaltrials.gov) - Feb 27, 2016
P3, N=260, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Not yet recruiting --> Enrolling by invitation No longer recruiting --> Completed
- |||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults (clinicaltrials.gov) - Feb 23, 2016
P3, N=520, Recruiting, Sponsor: Gilead Sciences
No longer recruiting --> Completed Trial primary completion date: Apr 2017 --> Jul 2017
- ||||| Tybost (cobicistat) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Enrollment closed: Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (clinicaltrials.gov) - Feb 16, 2016
P2/3, N=100, Active, not recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Apr 2017 --> Jul 2017 Recruiting --> Active, not recruiting
- |||| Selzentry (maraviroc) / ViiV Healthcare, Prezista (darunavir) / J&J
Trial completion, Enrollment change: CogUK: Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa (clinicaltrials.gov) - Feb 12, 2016
P4, N=60, Completed, Sponsor: Imperial College London
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=50 --> 60
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion, Trial primary completion date: MARCHrenal: MARCH Renal Substudy (clinicaltrials.gov) - Jan 20, 2016
P4, N=76, Completed, Sponsor: Kirby Institute
Active, not recruiting --> Completed | N=50 --> 60 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion, Trial primary completion date: MARCH Central Nervous System Substudy (clinicaltrials.gov) - Jan 20, 2016
P=N/A, N=28, Completed, Sponsor: Kirby Institute
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion, Trial primary completion date: MARCH VE: MARCH Vascular Endothelium Substudy (clinicaltrials.gov) - Jan 20, 2016
P=N/A, N=34, Completed, Sponsor: Kirby Institute
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015
- Adempas (riociguat) / Bayer, Merck (MSD)
Trial primary completion date: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Jan 17, 2016
P1, N=40, Not yet recruiting, Sponsor: Bayer
Active, not recruiting --> Completed | Trial primary completion date: Jan 2015 --> Dec 2015 Trial primary completion date: Oct 2016 --> Jan 2018
- |||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Enrollment open: Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults (clinicaltrials.gov) - Dec 10, 2015
P3, N=520, Recruiting, Sponsor: Gilead Sciences
Trial primary completion date: Oct 2016 --> Jan 2018 Not yet recruiting --> Recruiting
- ||||| lamivudine / Generic mfg.
Enrollment closed, Trial primary completion date, Head-to-Head: MOBIDIP: Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa (clinicaltrials.gov) - Dec 10, 2015
P3, N=265, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016
- Prezista (darunavir) / J&J
Enrollment open: VIRECURE: Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection (clinicaltrials.gov) - Nov 27, 2015
P3, N=15, Recruiting, Sponsor: David Garcia Cinca
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Dec 2016 Not yet recruiting --> Recruiting
- Prezista (darunavir) / J&J
Enrollment closed: DARULIGHT: Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients (clinicaltrials.gov) - Nov 24, 2015
P2, N=100, Active, not recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting --> Recruiting Not yet recruiting --> Active, not recruiting
- |||||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
New P3 trial: Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults (clinicaltrials.gov) - Nov 14, 2015
P3, N=520, Not yet recruiting, Sponsor: Gilead Sciences
- Prezista (darunavir) / J&J
New P3 trial: VIRECURE: Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection (clinicaltrials.gov) - Oct 28, 2015
P3, N=15, Not yet recruiting, Sponsor: David Garcia Cinca
- Prezista (darunavir) / J&J, Isentress (raltegravir) / Merck (MSD)
Enrollment change, Trial termination, Trial primary completion date: Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR) (clinicaltrials.gov) - Oct 22, 2015
P3, N=4, Terminated, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting --> Active, not recruiting N=120 --> 4 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Sep 2015; Low recruitment of participants for the study
- Zolinza (vorinostat) / Merck (MSD), Selzentry (maraviroc) / ViiV Healthcare
Enrollment closed: Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection (clinicaltrials.gov) - Oct 8, 2015
P1/2, N=15, Active, not recruiting, Sponsor: South East Asia Research Collaboration with Hawaii
N=120 --> 4 | Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Sep 2015; Low recruitment of participants for the study Recruiting --> Active, not recruiting
- ||| Isentress (raltegravir) / Merck (MSD)
Enrollment closed: RANIA: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (clinicaltrials.gov) - Oct 8, 2015
P2, N=100, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Adempas (riociguat) / Bayer, Merck (MSD)
New P1 trial: Interaction With HIV Antiretroviral Agents (clinicaltrials.gov) - Sep 22, 2015
P1, N=40, Not yet recruiting, Sponsor: Bayer
- |||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF (clinicaltrials.gov) - Aug 21, 2015
P3, N=665, Active, not recruiting, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2015 --> Aug 2015
- Tivicay (dolutegravir) / ViiV Healthcare
New P4 trial: HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen (clinicaltrials.gov) - Jul 31, 2015
P4, N=44, Recruiting, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
- Zolinza (vorinostat) / Merck (MSD), Selzentry (maraviroc) / ViiV Healthcare
New P1/2 trial: Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection (clinicaltrials.gov) - Jun 20, 2015
P1/2, N=15, Recruiting, Sponsor: South East Asia Research Collaboration with Hawaii
- |||||| Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
Enrollment open, Combination therapy: DRIVE-SHIFT: Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (clinicaltrials.gov) - Jun 20, 2015
P3, N=660, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Nov 2015 --> Aug 2015 Not yet recruiting --> Recruiting
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P4 trial, HEOR, Cost effectiveness: Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (clinicaltrials.gov) - Jun 12, 2015
P4, N=150, Not yet recruiting, Sponsor: Juan A. Arnaiz
- |||| Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
Trial primary completion date, Combination therapy: DRIVE-SHIFT: Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (clinicaltrials.gov) - Jun 11, 2015
P3, N=660, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2017 --> Mar 2017
- Prezista (darunavir) / J&J, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial primary completion date: QuaDar: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy (clinicaltrials.gov) - Jun 11, 2015
P4, N=10, Recruiting, Sponsor: University of British Columbia
Trial primary completion date: Jun 2017 --> Mar 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- | Selzentry (maraviroc) / ViiV Healthcare, Prezista (darunavir) / J&J
Enrollment closed, Trial primary completion date: CogUK: Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa (clinicaltrials.gov) - Jun 4, 2015
P4, N=50, Active, not recruiting, Sponsor: Imperial College London
Trial primary completion date: Dec 2015 --> Dec 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Nov 2015
- ||||||| Vitekta (elvitegravir) / Japan Tobacco, Gilead
Trial completion: Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir (clinicaltrials.gov) - May 26, 2015
P3, N=724, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2015 --> Nov 2015 Active, not recruiting --> Completed
- |||||| Prezista (darunavir) / J&J, Isentress (raltegravir) / Merck (MSD)
Enrollment open: Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR) (clinicaltrials.gov) - May 12, 2015
P3, N=120, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults (clinicaltrials.gov) - May 7, 2015
P3, N=170, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Trial primary completion date: Feb 2015 --> Aug 2015
- Prezista (darunavir) / J&J, Tivicay (dolutegravir) / ViiV Healthcare, Vemlidy (tenofovir alafenamide) / Gilead
New P1 trial: HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS) (clinicaltrials.gov) - May 7, 2015
P1, N=20, Enrolling by invitation, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
- ||| Prezista (darunavir) / J&J
Enrollment change: Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment (clinicaltrials.gov) - May 2, 2015
P4, N=68, Completed, Sponsor: Tibotec, Inc
Trial primary completion date: Feb 2015 --> Aug 2015 N=86 --> 68
- |||||||||| Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) / Merck (MSD)
New P3 trial, Combination therapy: DRIVE-SHIFT: Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (clinicaltrials.gov) - Mar 26, 2015
P3, N=660, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||||||| Tybost (cobicistat) / Gilead
Trial completion: Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment (clinicaltrials.gov) - Mar 17, 2015
P3, N=106, Completed, Sponsor: Gilead Sciences
N=86 --> 68 Active, not recruiting --> Completed
- || Isentress (raltegravir) / Merck (MSD)
Trial primary completion date: RANIA: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (clinicaltrials.gov) - Mar 11, 2015
P2, N=100, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Aug 2016
- | Prezista (darunavir) / J&J
New P2 trial: DARULIGHT: Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients (clinicaltrials.gov) - Mar 10, 2015
P2, N=100, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- | Enrollment open: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Feb 19, 2015
P3, N=250, Recruiting, Sponsor: University Hospital, Tours
Trial primary completion date: Oct 2015 --> Aug 2016 Not yet recruiting --> Recruiting
- Selzentry (maraviroc) / ViiV Healthcare
Trial completion, Trial primary completion date, IO biomarker: Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen (clinicaltrials.gov) - Feb 11, 2015
P2, N=262, Completed, Sponsor: AIDS Clinical Trials Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jun 2014
- ||||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients (clinicaltrials.gov) - Jan 26, 2015
P3, N=438, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed | Trial primary completion date: Sep 2014 --> Jun 2014 Active, not recruiting --> Completed
- |||| Tybost (cobicistat) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead
Trial primary completion date: Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (clinicaltrials.gov) - Jan 6, 2015
P2/3, N=100, Recruiting, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Trial primary completion date: Aug 2017 --> Dec 2020
- Prezista (darunavir) / J&J, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New P2 trial: Clinical trial to determinate viral load in seminal fluid in HIV-positive patients without previous treatment Ensayo clinico para medir la carga viral en el semen de pacientes VIH que no han recibido tratamiento antirretroviral previamente (EUDRACT) - Dec 12, 2014
P2, N=36, Ongoing, Sponsor: Fundaci
- || New P3 trial: TRULIGHT: Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (clinicaltrials.gov) - Nov 28, 2014
P3, N=250, Not yet recruiting, Sponsor: University Hospital, Tours
- Prezista (darunavir) / J&J, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment open: QuaDar: Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy (clinicaltrials.gov) - Nov 12, 2014
P4, N=10, Recruiting, Sponsor: University of British Columbia
Trial primary completion date: Aug 2017 --> Dec 2020 Not yet recruiting --> Recruiting
- |||||||||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead
New P2/3 trial: Study To Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in Human Immunodeficiency Virus 1 (HIV-1) Infected Children and Adolescents Virologically Suppressed on a 2- Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (2-NRTI)-Containing Regimen (clinicaltrials.gov) - Nov 6, 2014
P2/3, N=100, Recruiting, Sponsor: Gilead Sciences
- ||||||| Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial completion: Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF (clinicaltrials.gov) - Nov 6, 2014
P3, N=482, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion, Trial primary completion date: Changes in Insulin Resistance in Healthy Volunteers on STRIBILD (clinicaltrials.gov) - Nov 5, 2014
P1, N=30, Completed, Sponsor: Technische Universit
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Oct 2014
- |||||| lamivudine / Generic mfg.
Enrollment open, Head-to-Head: MOBIDIP: Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa (clinicaltrials.gov) - Nov 4, 2014
P3, N=264, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting --> Completed | Trial primary completion date: Apr 2015 --> Oct 2014 Active, not recruiting --> Recruiting
- |||| Isentress (raltegravir) / Merck (MSD)
Enrollment open: RANIA: Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) (clinicaltrials.gov) - Oct 2, 2014
P2, N=100, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Prezista (darunavir) / J&J, Isentress (raltegravir) / Merck (MSD)
New P3 trial: Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR) (clinicaltrials.gov) - Sep 28, 2014
P3, N=120, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)